Roivant Sciences, Inc.
NEWS
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
Tapinarof’s potential remittive effects could hold even more value for long-term psoriasis suffers. For patients coming into the trial with a PGA score of 0 (n=78), median time to the disease worsening (defined as a PGA score of ≥2) after discontinuing treatment was approximately 115 days, or 4 months.
If you know Roivant as a brand you might be familiar with Vivek Ramaswamy too. Recently, he stepped down as CEO and became Executive Chairman. Let’s know more.
Roivant Sciences announced its targeted protein degradation platform, with its first pipeline candidate expected to enter the clinic in 2021.
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Roivant Sciences, helmed by biotech billionaire Vivek Ramaswamy, launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
JOBS
IN THE PRESS